Tomas Kiselak - 03 Jun 2021 Form 4 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)

Reporting relationship: Director
Issuer ticker: VRDN
Reported as of: 03 Jun 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Jun 2021, 18:34:47 UTC
Next SEC filing: 10 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ Lara Meisner, Attorney-in-Fact for Tomas Kiselak

Key filing fact

Tomas Kiselak filed Form 4 for Viridian Therapeutics, Inc.\DE (VRDN) on 16 Jun 2021.

Key facts

This page summarizes Tomas Kiselak's Form 4 filing for Viridian Therapeutics, Inc.\DE (VRDN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 16 Jun 2021, 18:34.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VRDN transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +12,500
Change %
Price: $0.000000
Shares after: 12,500
Date: 03 Jun 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,500
Exercise price: $16.60
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests in full upon the earlier to occur of (i) June 3, 2022 or (ii) the Issuer's 2022 annual meeting of stockholders, subject to Reporting Person's continued service on the Board.